Health care stocks were advancing premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Novartis (NVS) will keep manufacturing treatments for malaria and leprosy even if regular orders stop due to global health funding cuts, Reuters reported, citing its global health president. The company's shares were down more than 2% pre-bell.
ImmunityBio (IBRX) stock was up more than 4% after the company reported a narrower Q1 net loss as revenue increased during the period.
Dr. Reddy's Laboratories (RDY) shares were up past 3% after the company posted higher fiscal Q4 earnings and revenue.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。